APRI has Utility as a Biomarker of COVID-19 Severity in Patients with Nonalcoholic Fatty Liver Disease.

Hiroaki TakayaShunichi UeyamaYui OsakiKosuke KajiHideto KawarataniKo SaitoShigeyuki AizawaTadashi NamisakiChie MoriokaMotoyuki YoshidaTakemi AkahaneHitoshi Yoshiji

Published in: Hepatology research : the official journal of the Japan Society of Hepatology (2023)

APRI was independently associated with COVID-19 severity and hospitalization duration for COVID-19 in patients with NAFLD.

Keyphrases

coronavirus disease
sars cov
respiratory syndrome coronavirus